Aldosterone Synthase Inhibitors — PatSnap Eureka
Aldosterone Synthase Inhibitors: Baxdrostat, Lorundrostat & the CKD Pipeline
CYP11B2 is the exclusive biosynthetic gateway to aldosterone. Three independent programs — AstraZeneca, Mineralys Therapeutics, and Boehringer Ingelheim — are converging on aldosterone synthase inhibitors combined with SGLT2 inhibitors as the next standard-of-care for resistant hypertension and CKD.
Why CYP11B2 Inhibition Addresses an Unmet Need in Resistant Hypertension and CKD
Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 enzyme residing in the zona glomerulosa of the adrenal cortex. It catalyzes a three-step conversion of 11-deoxycorticosterone (11-DOC) to aldosterone — via corticosterone and 18-hydroxycorticosterone — making it the exclusive biosynthetic gateway to aldosterone production. Unlike mineralocorticoid receptor antagonists (MRAs), which act downstream, aldosterone synthase inhibitors (ASIs) act upstream on synthesis itself.
In resistant hypertension, life sciences drug intelligence from retrieved records shows that mineralocorticoid receptor blockade with spironolactone achieves the greatest incremental blood pressure reduction — but is complicated by hyperkalemia, particularly in patients with concomitant CKD or heart failure. Patients experiencing hyperkalemia on RAAS inhibitors face dose reduction or discontinuation, with cardiorenal morbidity and mortality occurring in 34.3% of those who discontinued versus 24.9% of those on submaximum doses.
In CKD, aldosterone drives renal fibrosis, epithelial-to-mesenchymal transition (via mitochondrial reactive oxygen species), and albuminuria progression. Retrieved patents from patent analytics searches confirm that aldosterone blockade in preclinical CKD and diabetic nephropathy models reduces renal fibrosis, improves glomerular filtration rate (GFR), and ameliorates albuminuria. The "aldosterone escape" phenomenon — whereby ACE inhibitor or ARB therapy fails to sustain aldosterone suppression over chronic treatment — is cited across multiple retrieved records as the key unmet need driving ASI development.
A key selectivity constraint noted across retrieved Mineralys Therapeutics patents is that CYP11B2 shares >93% amino acid sequence homology with CYP11B1 (the glucocorticoid biosynthesis enzyme), making selectivity for CYP11B2 over CYP11B1 an essential design criterion to avoid cortisol suppression. This challenge has historically prevented earlier structural series from Novartis and Roche from reaching approval.
Baxdrostat, Lorundrostat, and the Emerging ASI Landscape
Three programs dominate active IP prosecution in the aldosterone synthase inhibitor space, with distinct clinical positioning, dosing strategies, and combination approaches.
Baxdrostat — Selective ASI for CKD + Hypertension
Described across multiple AstraZeneca filings as "a highly selective aldosterone synthase inhibitor that can significantly reduce aldosterone levels, offering the potential to not only improve BP in patients with CKD, but also ameliorate the negative impacts of elevated aldosterone on kidney function." Being developed in combination with dapagliflozin (SGLT2 inhibitor). Active patent prosecution in WO and TW jurisdictions with filings as recent as June 2025. AstraZeneca describes baxdrostat and dapagliflozin as having "different and complementary mechanisms of actions" that "may provide particular benefits in slowing the progression of CKD."
WO + TW · June 2025 filing · eGFR slope endpointLorundrostat — Periodic CYP11B2 Suppression Strategy
Covered in multiple jurisdictions (WO, AU, TW, ID, US, CA) by patents describing CYP11B2 inhibition via dosing regimens designed to inhibit ≥50% of CYP11B2 activity for 40–60% of a 24-hour period — a "periodic suppression" strategy intended to preserve physiological aldosterone oscillation while controlling pathological elevations. Once- or twice-daily dosing claimed for both hypertension and CKD indications. The most prolific filer in this dataset, with 5 distinct patent records spanning multiple jurisdictions from 2023 to February 2026 (AU). MRA hyperkalemia rates (~10% clinically meaningful incidence) cited as key differentiation rationale.
5 patent records · WO/AU/CA/US/TW/ID · 2023–2026Proprietary ASI Program — Broad CKD Use-Patent Estate
Multiple filings across structural chemistry (ASI Formula I compounds, 2019) and therapeutic use (CKD, 2023–2024) with explicit SGLT2 combination claims. Formula I compounds bear -C(O)NH₂, -C(O)NHCH₃, or -CN at R1, with heterocyclyl and alkyl R2/R4 substitutions. Geographic spread of CKD-use patents now covers 7 jurisdictions: CA, TW, KR, CL, BR, CN, and additional filings. No named compound is disclosed in retrieved records, but multi-jurisdictional therapeutic use prosecution is consistent with an IND-enabling or early clinical stage program. Combination with empagliflozin (SGLT2i) explicitly claimed.
7 jurisdictions · Undisclosed compound · SGLT2i combination claimedNovartis, Roche & Japan Tobacco — Structural IP and Emerging Entrants
Novartis AG filed condensed imidazolo derivatives (2013, ES) and aryl pyridine derivatives (2014, RS) as ASI scaffold series — most filings now inactive or lapsed, suggesting these structural series are no longer actively prosecuted. F. Hoffmann-La Roche AG filed dihydroquinolinone and bicyclic dihydroisoquinolinone ASI scaffolds (2020–2021, ES/RS) with mixed active/inactive legal status and no corresponding therapeutic use claims for CKD or hypertension retrieved. Japan Tobacco Inc. filed a 2023 TW-pending application covering nitrogen-containing tricyclic compounds across cardiorenal indications including CKD, heart failure, and pulmonary hypertension — representing a non-Western entrant into the CYP11B2 inhibitor space.
Novartis/Roche largely lapsed · Japan Tobacco 2023 TW pendingPatent Activity and Clinical Evidence Across the ASI Landscape
Key quantitative signals from retrieved patent and literature records, illustrating the competitive IP landscape and clinical rationale for aldosterone synthase inhibition.
ASI Patent Records by Assignee in This Dataset
Mineralys Therapeutics leads with 5 distinct records; Boehringer Ingelheim covers 7 jurisdictions with therapeutic-use filings from 2023–2024.
eGFR Decline: Spironolactone vs. Furosemide in Resistant Hypertension + CKD
Prospective study (n=30, 32-month follow-up, Hospital Gregorio Marañón) showed spironolactone significantly attenuated annual eGFR decline versus furosemide (p<0.01).
Cardiorenal Morbidity & Mortality: RAAS Inhibitor Discontinuation vs. Submaximum Dose
Hyperkalemia-driven RAAS inhibitor discontinuation results in 34.3% cardiorenal morbidity/mortality vs. 24.9% on submaximum doses — the key unmet need ASIs address.
Lorundrostat Periodic CYP11B2 Suppression Strategy (24-Hour Window)
Mineralys Therapeutics patents claim ≥50% CYP11B2 inhibition for 40–60% of a 24-hour period, preserving physiological aldosterone oscillation while controlling pathological peaks.
ASI + SGLT2 Inhibitor: The Dominant Emerging IP Theme
Three independent programs are converging on ASI + SGLT2 inhibitor combinations as the next-generation regimen for CKD and resistant hypertension, citing complementary and potentially synergistic mechanisms.
AstraZeneca: Baxdrostat + Dapagliflozin
A June 2025 WO patent filing explicitly frames baxdrostat + dapagliflozin as a regimen addressing both blood pressure and kidney function endpoints in CKD + hypertension patients, referencing eGFR slope as a relevant outcome measure. AstraZeneca describes the two agents as having "different and complementary mechanisms of actions" that "may provide particular benefits in slowing the progression of CKD." A July 2025 Taiwan filing covering "methods of treating CKD and hypertension" reflects contemporaneous multi-jurisdictional prosecution.
Mineralys: Lorundrostat + SGLT2 Inhibitor
Retrieved Mineralys patents cite the CREDENCE and DAPA-CKD trials as establishing SGLT2 inhibitor efficacy in diabetic and non-diabetic CKD respectively, positioning ASI + SGLT2i combination as a logical next-generation regimen. The Mineralys WO filing (2025) covers CKD treatment alone or with hypertension, using lorundrostat alone or in combination with a SGLT2 inhibitor. MRA hyperkalemia rates (~10% clinically meaningful incidence) are cited as the key differentiation rationale for lorundrostat in this context.
Assignee Patent Activity: Program Status and Jurisdiction Coverage
Comparative overview of the five key assignees in the ASI patent dataset, their program stage, geographic IP coverage, and combination strategy positioning.
| Assignee | Lead Agent | Program Stage | Key Jurisdictions | SGLT2i Combination | Latest Filing |
|---|---|---|---|---|---|
| AstraZeneca Ireland Ltd. | Baxdrostat | Clinical | WO, TW | Dapagliflozin ✓ | June 2025 (WO) |
| Mineralys Therapeutics | Lorundrostat | Clinical | WO, AU, CA, US, TW, ID | SGLT2i ✓ | Feb 2026 (AU) |
| Boehringer Ingelheim | Undisclosed (Formula I) | IND-Enabling | CA, TW, KR, CL, BR, CN, JP | Empagliflozin ✓ | 2024 (KR, CL) |
| Novartis AG | Imidazolo / Aryl pyridine | Lapsed | ES, RS, MX | AT1 + diuretic (historical) | 2014 (RS) |
| F. Hoffmann-La Roche AG | Dihydroquinolinone / Bicyclic | Mixed / Preclinical | ES, RS | None retrieved | 2021 (ES) |
Monitor Boehringer Ingelheim's Undisclosed ASI Compound
The filing pattern across 7+ jurisdictions suggests IND-enabling stage. Identify the compound via PatSnap Eureka's clinical trial registry cross-referencing.
What the ASI Patent Landscape Means for Drug Developers and IP Teams
Baxdrostat + dapagliflozin (AstraZeneca) represents the most advanced combination IP in this dataset, with a June 2025 WO filing suggesting proximity to or ongoing Phase 2/3 clinical evaluation. Developers and investors should monitor AstraZeneca's CKD combination trial readouts as potential inflection points for the entire ASI class. The ClinicalTrials.gov registry and EMA trial databases are the primary sources for tracking baxdrostat's clinical progression.
Lorundrostat's "periodic suppression" dosing strategy is a distinctive IP differentiator. Mineralys Therapeutics has built a multi-jurisdictional IP estate around a specific pharmacodynamic window for CYP11B2 inhibition (≥50% inhibition for 40–60% of a 24-hour period), which if clinically validated could create durable IP moats and a differentiated safety profile relative to continuous MRAs. The IP analytics platform at PatSnap can track the prosecution status of each Mineralys filing across WO, AU, CA, US, TW, and ID jurisdictions in real time.
The CYP11B2/CYP11B1 selectivity challenge remains a key technical barrier. Retrieved data from Mineralys explicitly note >93% sequence homology between these enzymes, and the early Novartis/Roche programs generated structural IP that did not yield approved drugs — signaling that structural selectivity is achievable in theory but has historically been difficult to translate clinically. Medicinal chemists and IP analysts should scrutinize selectivity data as a differentiating criterion when evaluating ASI programs.
The combination of ASI + SGLT2 inhibitor as a next standard-of-care for CKD + hypertension is the dominant emerging IP theme across multiple assignees. Retrieved academic literature from kidney outcome trials (CREDENCE, DAPA-CKD, referenced in Mineralys filings) provides the clinical context. Licensing, co-development, or fixed-dose combination (FDC) opportunities across these programs may be of interest to business development teams. The PatSnap customer case studies page documents how BD teams use patent intelligence to identify such opportunities.
Aldosterone Synthase Inhibitors — key questions answered
Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 enzyme residing in the zona glomerulosa of the adrenal cortex. It catalyzes a three-step conversion of 11-deoxycorticosterone (11-DOC) to aldosterone (via corticosterone and 18-hydroxycorticosterone), making it the exclusive biosynthetic gateway to aldosterone production. In resistant hypertension and CKD, blocking this enzyme upstream of the mineralocorticoid receptor offers the potential to reduce aldosterone-driven sodium retention and fibrosis without the hyperkalemia associated with MR antagonists.
Baxdrostat is described across multiple AstraZeneca filings as a highly selective aldosterone synthase inhibitor that can significantly reduce aldosterone levels, offering the potential to not only improve BP in patients with CKD, but also ameliorate the negative impacts of elevated aldosterone on kidney function. It is being developed in combination with dapagliflozin (SGLT2 inhibitor) for CKD and hypertension, with active patent prosecution in WO and TW jurisdictions as recently as June 2025.
Mineralys Therapeutics' patents describe CYP11B2 inhibition via dosing regimens designed to inhibit ≥50% of CYP11B2 activity for 40–60% of a 24-hour period — a periodic suppression strategy intended to preserve physiological aldosterone oscillation while controlling pathological elevations. These patents describe once- or twice-daily dosing and claim treatment of both hypertension and CKD.
CYP11B2 shares greater than 93% amino acid sequence homology with CYP11B1 (the glucocorticoid biosynthesis enzyme), making selectivity for CYP11B2 over CYP11B1 an essential design criterion to avoid cortisol suppression. This structural similarity is a key technical barrier for ASI drug development and is explicitly noted across retrieved Mineralys Therapeutics patents.
Three independent programs — AstraZeneca (baxdrostat + dapagliflozin), Boehringer Ingelheim (proprietary ASI + SGLT2i), and Mineralys (lorundrostat + SGLT2i) — are independently filing IP covering this combination in CKD and/or hypertension. The mechanistic rationale cited across filings is complementarity: SGLT2 inhibitors reduce intraglomerular hypertension and have demonstrated kidney outcomes benefits (CREDENCE, DAPA-CKD); ASIs reduce aldosterone-driven fibrosis, sodium retention, and MR-mediated nephropathy.
A prospective study of 30 patients with resistant hypertension from Hospital Gregorio Marañón (Madrid) showed spironolactone reduced mean annual eGFR decline (−2.1 ± 4.8 vs. −3.2 ± 5.6 ml/min/1.73 m² in the furosemide group, p less than 0.01) and reduced systolic blood pressure over a median 32-month follow-up. Academic literature also notes that patients experiencing hyperkalemia on RAAS inhibitors are subject to dose reduction or discontinuation, with cardiorenal morbidity and mortality occurring in 34.3% of those who discontinued versus 24.9% of those on submaximum doses.
Still have questions about the ASI pipeline? Let PatSnap Eureka search the patent literature for you.
Ask PatSnap Eureka Your ASI QuestionAccelerate Your CKD and Resistant Hypertension Drug Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track the ASI pipeline, map IP white space, and identify combination opportunities across baxdrostat, lorundrostat, and emerging CYP11B2 programs.
References
- Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers — Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 2021 [Paper]
- Aldosterone synthase inhibitors — Boehringer Ingelheim International GmbH, 2019, JP [Patent]
- Methods of treating hypertension by periodic suppression of aldosterone synthase — Mineralys Therapeutics, Inc., 2023, CA [Patent]
- SGLT2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension — AstraZeneca Ireland Limited, 2025, WO [Patent]
- Methods of treating chronic kidney disease and hypertension — AstraZeneca Ireland Limited (Taiwan subsidiary), 2025, TW [Patent]
- Methods of treating hypertension by periodic suppression of aldosterone synthase — Mineralys Therapeutics, Inc., 2025, US [Patent]
- Aldosterone synthase inhibitors for treating chronic kidney disease — Boehringer Ingelheim International GmbH, 2023, CA [Patent]
- Aldosterone synthase inhibitors for treating chronic kidney disease — Boehringer Ingelheim International GmbH, 2024, CL [Patent]
- Aldosterone synthase inhibitors for the treatment of chronic kidney disease — Boehringer Ingelheim International GmbH, 2024, KR [Patent]
- Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase — Novartis AG, 2013, ES [Patent]
- Aryl pyridine as aldosterone synthase inhibitors — Novartis AG, 2014, RS [Patent]
- Dihydroquinolin-2-one derivatives for use as aldosterone synthase inhibitors — F. Hoffmann-La Roche AG, 2021, ES [Patent]
- New dihydroquinoline-2-one derivatives — F. Hoffmann-La Roche AG, 2020, RS [Patent]
- New bicyclic dihydroisoquinolin-1-one derivatives — F. Hoffmann-La Roche AG, 2021, ES [Patent]
- Aldosterone synthase inhibitors — Boehringer Ingelheim International GmbH, 2019, ES [Patent]
- Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists — Departamento Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, 2020 [Paper]
- Aldosterone synthase inhibitors and their uses in the treatment of chronic kidney disease — Boehringer Ingelheim International GmbH, 2024, BR [Patent]
- Methods of treating chronic kidney disease (CKD) or CKD and hypertension with lorundrostat, or a combination of lorundrostat and a SGLT2 inhibitor — Mineralys Therapeutics, Inc., 2025, WO [Patent]
- Methods of treating chronic kidney disease (CKD) or CKD and hypertension with lorundrostat, or a combination of lorundrostat and a SGLT2 inhibitor — Mineralys Therapeutics, Inc., 2026, AU [Patent]
- Combination of organic compounds — Novartis AG, 2003, MX [Patent]
- Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin–angiotensin–aldosterone system among patients with obesity and proteinuria — Department of Nephrology, Hospital 12 de Octubre, Madrid, 2015 [Paper]
- Nitrogen-containing tricyclic compound and pharmaceutical use thereof — Japan Tobacco Inc., 2023, TW [Patent]
- ClinicalTrials.gov — U.S. National Library of Medicine clinical trial registry
- European Medicines Agency (EMA) — EU clinical trial database and regulatory intelligence
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.